315 related articles for article (PubMed ID: 9647741)
1. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.
Mizuno A; Amizuka N; Irie K; Murakami A; Fujise N; Kanno T; Sato Y; Nakagawa N; Yasuda H; Mochizuki S; Gomibuchi T; Yano K; Shima N; Washida N; Tsuda E; Morinaga T; Higashio K; Ozawa H
Biochem Biophys Res Commun; 1998 Jun; 247(3):610-5. PubMed ID: 9647741
[TBL] [Abstract][Full Text] [Related]
2. A novel molecular mechanism modulating osteoclast differentiation and function.
Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
[TBL] [Abstract][Full Text] [Related]
3. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
Yasuda H; Shima N; Nakagawa N; Mochizuki SI; Yano K; Fujise N; Sato Y; Goto M; Yamaguchi K; Kuriyama M; Kanno T; Murakami A; Tsuda E; Morinaga T; Higashio K
Endocrinology; 1998 Mar; 139(3):1329-37. PubMed ID: 9492069
[TBL] [Abstract][Full Text] [Related]
4. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
Mochizuki S; Kiyokawa A; Nagayama Y
Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells.
Takai H; Kanematsu M; Yano K; Tsuda E; Higashio K; Ikeda K; Watanabe K; Yamada Y
J Biol Chem; 1998 Oct; 273(42):27091-6. PubMed ID: 9765225
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice.
Kawana F; Sasaki T
J Electron Microsc (Tokyo); 2003; 52(6):515-25. PubMed ID: 14756239
[TBL] [Abstract][Full Text] [Related]
7. Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice.
Yamazaki H; Sasaki T
J Electron Microsc (Tokyo); 2005 Oct; 54(5):467-77. PubMed ID: 16339792
[TBL] [Abstract][Full Text] [Related]
8. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells.
Kanzawa M; Sugimoto T; Kanatani M; Chihara K
Eur J Endocrinol; 2000 Jun; 142(6):661-4. PubMed ID: 10822231
[TBL] [Abstract][Full Text] [Related]
9. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
Hofbauer LC; Khosla S; Dunstan CR; Lacey DL; Boyle WJ; Riggs BL
J Bone Miner Res; 2000 Jan; 15(1):2-12. PubMed ID: 10646108
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function.
Shimizu-Ishiura M; Kawana F; Sasaki T
J Electron Microsc (Tokyo); 2002; 51(5):315-25. PubMed ID: 12455916
[TBL] [Abstract][Full Text] [Related]
11. [Osteoclastogenesis inhibitory factor (OCIF)/OPG].
Tsuda E; Higashio K
Nihon Rinsho; 1998 Jun; 56(6):1435-9. PubMed ID: 9648461
[TBL] [Abstract][Full Text] [Related]
12. [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)].
Inoue D
Nihon Rinsho; 2004 Feb; 62 Suppl 2():102-6. PubMed ID: 15035105
[No Abstract] [Full Text] [Related]
13. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
[TBL] [Abstract][Full Text] [Related]
14. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
15. Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy.
Yano K; Shibata O; Mizuno A; Kobayashi F; Higashio K; Morinaga T; Tsuda E
Biochem Biophys Res Commun; 2001 Oct; 288(1):217-24. PubMed ID: 11594776
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
17. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.
Tsukii K; Shima N; Mochizuki S; Yamaguchi K; Kinosaki M; Yano K; Shibata O; Udagawa N; Yasuda H; Suda T; Higashio K
Biochem Biophys Res Commun; 1998 May; 246(2):337-41. PubMed ID: 9610359
[TBL] [Abstract][Full Text] [Related]
18. [Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)].
Tomoyasu A; Higashio K
Nihon Rinsho; 2004 Feb; 62 Suppl 2():560-5. PubMed ID: 15035190
[No Abstract] [Full Text] [Related]
19. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.
Min H; Morony S; Sarosi I; Dunstan CR; Capparelli C; Scully S; Van G; Kaufman S; Kostenuik PJ; Lacey DL; Boyle WJ; Simonet WS
J Exp Med; 2000 Aug; 192(4):463-74. PubMed ID: 10952716
[TBL] [Abstract][Full Text] [Related]
20. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
